
# 2023-09-30
## Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer
## （LNK对JAK-STAT信号传导的调节：激素受体阳性乳腺癌中被遗忘的致癌途径）
## https://www.mdpi.com/1422-0067/24/19/14777
- Breast cancer remains the most frequently diagnosed cancer in women worldwide. Tumors that express hormone receptors account for 75% of all cases. Understanding alternative signaling cascades is important for finding new therapeutic targets for hormone receptor-positive breast cancer patients. JAK-STAT signaling is commonly activated in hormone receptor-positive breast tumors, inducing inflammation, proliferation, migration, and treatment resistance in cancer cells. In hormone receptor-positive breast cancer, the JAK-STAT cascade is stimulated by hormones and cytokines, such as prolactin and IL-6. In normal cells, JAK-STAT is inhibited by the action of the adaptor protein, LNK. However, the role of LNK in breast tumors is not fully understood. This review compiles published reports on the expression and activation of the JAK-STAT pathway by IL-6 and prolactin and potential inhibition of the cascade by LNK in hormone receptor-positive breast cancer. Additionally, it includes analyses of available datasets to determine the level of expression of LNK and various members of the JAK-STAT family for the purpose of establishing associations between expression and clinical outcomes. Together, experimental evidence and in silico studies provide a better understanding of the potential implications of the JAK-STAT-LNK loop in hormone receptor-positive breast cancer progression.
- （乳腺癌仍然是全世界女性最常被诊断出的癌症。表达激素受体的肿瘤占所有病例的75%。了解替代信号级联对于为激素受体阳性乳腺癌患者寻找新的治疗靶点非常重要。JAK-STAT信号传导通常在激素受体阳性乳腺肿瘤中激活，诱导癌细胞的炎症，增殖，迁移和治疗耐药性。在激素受体阳性乳腺癌中，JAK-STAT级联反应受到激素和细胞因子（如催乳素和IL-6）的刺激。在正常细胞中，JAK-STAT受到衔接蛋白LNK的作用的抑制。然而，LNK在乳腺肿瘤中的作用尚不完全清楚。本综述汇编了关于IL-6和催乳素对JAK-STAT通路的表达和激活以及LNK在激素受体阳性乳腺癌中级联反应的潜在抑制的已发表报告。此外，它还包括对可用数据集的分析，以确定LNK和JAK-STAT家族各种成员的表达水平，目的是建立表达与临床结果之间的关联。总之，实验证据和计算机研究提供了对JAK-STAT-LNK环在激素受体阳性乳腺癌进展中的潜在影响更好的理解。）
# 2023-09-19
## Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
## （百里醌，一种新型促肿瘤性乳腺癌（BC）标志物的多重打击抑制剂：HR +和TNBC患者PBMC中的CALR，NLRP3通路和sPD-L1）
## https://www.mdpi.com/1422-0067/24/18/14254
- Breast cancer (BC) is not only a mass of malignant cells but also a systemic inflammatory disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and provoke BC progression. The NOD-like receptor (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome is activated when pattern recognition receptors (PRRs) sense danger signals such as calreticulin (CALR) from damaged/dying cells, leading to the secretion of interleukin-1β (IL-1β). CALR is a novel BC biological marker, and its high levels are associated with advanced tumors. NLRP3 expression is strongly correlated with an elevated proliferative index Ki67, BC progression, metastasis, and recurrence in patients with hormone receptor-positive (HR+) and triple-negative BC (TNBC). Tumor-associated macrophages (TAMs) secrete high levels of IL-1β promoting endocrine resistance in HR+ BC. Recently, an immunosuppressive soluble form of programmed death ligand 1 (sPD-L1) has been identified as a novel prognostic biomarker in triple-negative breast cancer (TNBC) patients. Interestingly, IL-1β induces sPD-L1 release. BC Patients with elevated IL-1β and sPD-L1 levels show significantly short progression-free survival. For the first time, this study aims to investigate the inhibitory impact of thymoquinone (TQ) on CALR, the NLRP3 pathway and sPD-L1 in HR+ and TNBC. Blood samples were collected from 45 patients with BC. The effect of differing TQ concentrations for different durations on the expression of CALR, NLRP3 complex components and IL-1β as well as the protein levels of sPD-L1 and IL-1β were investigated in the peripheral blood mononuclear cells (PBMCs) and TAMs of TNBC and HR+ BC patients, respectively. The findings showed that TQ significantly downregulated the expression of CALR, NLRP3 components and IL-1β together with the protein levels of secreted IL-1β and sPD-L1. The current findings demonstrated novel immunomodulatory effects of TQ, highlighting its potential role not only as an excellent adjuvant but also as a possible immunotherapeutic agent in HR+ and TNBC patients.
- （乳腺癌（BC）不仅是大量恶性细胞，还是一种全身性炎症性疾病。BC 促肿瘤性炎症已被证明可促进免疫逃避并引发 BC 进展。当模式识别受体 （PRR） 感知来自受损/垂死细胞的危险信号（例如钙网蛋白 （CALR））时，NOD 样受体 （NLR） 家族含 pyrin 结构域的蛋白 3 （NLRP3） 炎性小体被激活，导致白细胞介素-1β （IL-1β） 的分泌。CALR是一种新型BC生物标志物，其高水平与晚期肿瘤有关。NLRP3 表达与激素受体阳性 （HR+） 和三阴性 BC （TNBC） 患者的增殖指数 Ki67、BC 进展、转移和复发密切相关。肿瘤相关巨噬细胞（TAM）分泌高水平的IL-1β，促进HR + BC的内分泌抵抗。最近，免疫抑制可溶形式的程序性死亡配体1（sPD-L1）已被确定为三阴性乳腺癌（TNBC）患者的新型预后生物标志物。有趣的是，IL-1β诱导sPD-L1释放。IL-1β 和 sPD-L1 水平升高的 BC 患者表现出显著短的无进展生存期。本研究首次旨在研究胸腺醌（TQ）对HR +和TNBC中CALR，NLRP3途径和sPD-L1的抑制影响。从45例BC患者身上采集血液样本。研究了不同持续时间不同TQ浓度对TNBC和HR+ BC患者外周血单核细胞（PBMCs）和TAMsPD-L1和TAM表达的影响。 结果表明，TQ显著下调CALR、NLRP3组分和IL-1β的表达以及分泌的IL-1β和sPD-L1的蛋白水平。目前的研究结果证明了TQ的新型免疫调节作用，突出了其不仅作为优良佐剂的潜在作用，而且作为HR +和TNBC患者的可能免疫治疗剂。）
